The newest Market Talks overlaying the Health Care sector. Published solely on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0941 ET – An extended-term development driver for NeoGenomics could also be off the desk attributable to a patent-infringement lawsuit, Needham analysts say in a analysis notice. A North Carolina court docket issued a preliminary injunction in opposition to the corporate associated to its RaDaR check as a part of a patent go well with introduced by Natera. The analysts see the preliminary injunction as a nasty signal, since they’re hardly ever granted by courts and have a tendency to sign advantage within the underlying patent infringement case. Still, the analysts see NeoGenomics with different development catalysts from its medical companies and superior diagnostics companies. NeoGenomics plunges 19%, whereas Natera rises practically 4%. (ben.glickman@wsj.com; @benglickman)